Related Experiment Video

Updated: Apr 8, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K

OCT1 and imatinib transport in CML: is it clinically relevant?

D B Watkins1, T P Hughes1,2,3, D L White1,2,4

  • 1Leukaemia Research Group, Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.

Leukemia
|July 1, 2015
PubMed

Insights

The human organic cation transporter 1 (OCT1) influences imatinib uptake in chronic myeloid leukaemia (CML) cells. Measuring OCT1 activity and genetic variants can predict patient response to imatinib therapy.

Area of Science:

  • Pharmacology
  • Oncology
  • Genetics

Background:

  • Imatinib is a key therapy for chronic phase-chronic myeloid leukaemia (CP-CML).
  • Patient responses to imatinib can vary significantly.
  • The human organic cation transporter 1 (OCT1; SLC22A1) is implicated in imatinib cellular uptake.

Purpose of the Study:

  • To summarize the role of OCT1 and its genetic variants in imatinib uptake.
  • To discuss data assessing OCT1's function in imatinib transport.
  • To highlight OCT1's potential in predicting imatinib response in CP-CML patients.

Main Methods:

  • Review of existing literature on OCT1's role in imatinib transport.
  • Analysis of data from model systems investigating OCT1 function.
  • Correlation of OCT1 mRNA levels and functional activity with patient outcomes.

Main Results:

  • OCT1 is a primary transporter for imatinib into CML cells.
  • Variations in OCT1 efficiency affect imatinib influx and patient response.
  • OCT1 activity and genetic variants correlate with molecular response and outcomes in CP-CML.

Conclusions:

  • OCT1 plays a critical role in imatinib pharmacokinetics and pharmacodynamics.
  • Assessing OCT1 status can aid in personalizing imatinib treatment strategies for CP-CML.
  • Further research into OCT1 genetic variants may refine treatment prediction models.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.6K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
136
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
372
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
7.2K